Vedat Sansoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vedat Sansoy has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
Habib Haouala
18 shared publications- Izet Masic
Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
18 shared publications Kurt Huber
18 shared publications- Fausto José Pinto
University of Lisbon
17 shared publications Jean-Yves Artigou
15 shared publicationsEduard Apetrei
13 shared publications
Latest Publications
- Open Access
- 1 January 2017
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 45 (Suppl 3) , 1-4
The efficacy and safety of pitavastatin
In short-term, phase III or IV studies in Asian and European patients, pitavastatin 1, 2 and 4 mg once daily reduced LDL-Cholesterol (LDL-C) 34%, 42% and 47%, respectively. Pitavastatin provided sustained LDL-C-lowering efficacy over up to 60 weeks' therapy in extension studies. In comparative studies pitavastatin 4 mg and simvastatin 40 mg reduced LDL-C similarly, reduction in triglycerides and increase in HDL-Cholesterol (HDL-C) was more prominent with pitavastatin. In comparative studies with atorvastatin, pitavastatin 4mg was found to be more effective than 20 mg of atorvastatin, and a little less effective than 40 mg of atorvastatin. The increase in HDL-C demonstrated in short term studies sustained in long term, whereas with atorvastatin the increase in HDL-C was less prominent. Pitavastatin was generally well tolerated in these studies and most treatment emergent adverse events were mild or moderate and their frequency was not different from other statins. Pitavastatin did not appear to adversely affect glucose metabolism parameters (e.g. fasting blood glucose, fasting plasma insulin, glycated hemoglobin) in short- and longer-term prospective and post-marketing surveillance studies in adults. In conclusion, pitavastatin is an effective treatment option in adults with primary hypercholesterolemia and combined (mixed) dyslipidemia, including those at risk of developing type 2 diabetes.
- 1 January 2017
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 45 (Suppl 3) , 1-4
Open AccessThe efficacy and safety of pitavastatin
In short-term, phase III or IV studies in Asian and European patients, pitavastatin 1, 2 and 4 mg once daily reduced LDL-Cholesterol (LDL-C) 34%, 42% and 47%, respectively. Pitavastatin provided sustained LDL-C-lowering efficacy over up to 60 weeks' therapy in extension studies. In comparative studies pitavastatin 4 mg and simvastatin 40 mg reduced LDL-C similarly, reduction in triglycerides and increase in HDL-Cholesterol (HDL-C) was more prominent with pitavastatin. In comparative studies with atorvastatin, pitavastatin 4mg was found to be more effective than 20 mg of atorvastatin, and a little less effective than 40 mg of atorvastatin. The increase in HDL-C demonstrated in short term studies sustained in long term, whereas with atorvastatin the increase in HDL-C was less prominent. Pitavastatin was generally well tolerated in these studies and most treatment emergent adverse events were mild or moderate and their frequency was not different from other statins. Pitavastatin did not appear to adversely affect glucose metabolism parameters (e.g. fasting blood glucose, fasting plasma insulin, glycated hemoglobin) in short- and longer-term prospective and post-marketing surveillance studies in adults. In conclusion, pitavastatin is an effective treatment option in adults with primary hypercholesterolemia and combined (mixed) dyslipidemia, including those at risk of developing type 2 diabetes.
- 1 January 2016
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 44 (Supp:Suppl) , -26
Editör’den
- 1 January 2016
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 44 (Supp:Suppl) , -26
Editör’den
- Open Access
- 1 May 2015
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 34 (5) , 373-380
Fostering diffusion of scientific contents of National Society Cardiovascular Journals: The new ESC search engine
- 1 May 2015
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 34 (5) , 373-380
Open AccessFostering diffusion of scientific contents of National Society Cardiovascular Journals: The new ESC search engine
- 11 September 2013
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 43 (11) , 1129-1139
Abdominal obesity with hypertriglyceridaemia, lipoprotein(a) and apolipoprotein A‐I determine marked cardiometabolic risk
Background: Risks for coronary heart disease (CHD) and diabetes (T2DM) of the ‘hypertriglyceridemic waist’ phenotype (HtgW) warrant further investigation. We studied this issue and whether partial proinflammatory conversion of apolipoprotein (apo) A‐I by lipoprotein(a) [Lp(a)] is a codeterminant.Materials and Methods: In a population‐based prospective study, 1328 Turkish adults were analysed in four groups by the presence of abdominal obesity and elevated triglycerides (Htg).Results: LDL‐cholesterol levels, significantly elevated in isolated Htg, were lower in HtgW, yet significantly higher apoB and complement C3 values existed in women with HtgW in whom also the lowest Lp(a) values prevailed. Lp(a) was linearly associated, more strongly in HtgW than in the remaining groups, with apoB and, in women inversely, with gamma‐glutamyltransferase. Incident HtgW was predicted, not in men, but in women inversely by Lp(a) (OR 0·80 [95%CI 0·65; 0·97]), regardless of adjustment for relevant confounders. After adjustment for conventional risk factors, HtgW (OR 2·84) and high apoA‐I/HDL‐C ratio (OR 1·50) were significantly and additively associated with combined prevalent and incident CHD risk. High apoA‐I and low HDL‐cholesterol levels interacted therein in women. Type‐2 diabetes was strongly predicted by HtgW, mediated in men by high apoA‐I/HDL‐C ratio.Conclusion: HtgW is associated with excess inflammatory markers, is predicted in women paradoxically by lower circulating Lp(a) and is associated in both sexes with marked excess cardiometabolic risk to which high apoA‐I/HDL‐C ratio contributes additively. These findings are consistent in women with apoA‐I being oxidized via aggregation to Lp(a).
- 11 September 2013
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 43 (11) , 1129-1139
Abdominal obesity with hypertriglyceridaemia, lipoprotein(a) and apolipoprotein A‐I determine marked cardiometabolic risk
Background: Risks for coronary heart disease (CHD) and diabetes (T2DM) of the ‘hypertriglyceridemic waist’ phenotype (HtgW) warrant further investigation. We studied this issue and whether partial proinflammatory conversion of apolipoprotein (apo) A‐I by lipoprotein(a) [Lp(a)] is a codeterminant.Materials and Methods: In a population‐based prospective study, 1328 Turkish adults were analysed in four groups by the presence of abdominal obesity and elevated triglycerides (Htg).Results: LDL‐cholesterol levels, significantly elevated in isolated Htg, were lower in HtgW, yet significantly higher apoB and complement C3 values existed in women with HtgW in whom also the lowest Lp(a) values prevailed. Lp(a) was linearly associated, more strongly in HtgW than in the remaining groups, with apoB and, in women inversely, with gamma‐glutamyltransferase. Incident HtgW was predicted, not in men, but in women inversely by Lp(a) (OR 0·80 [95%CI 0·65; 0·97]), regardless of adjustment for relevant confounders. After adjustment for conventional risk factors, HtgW (OR 2·84) and high apoA‐I/HDL‐C ratio (OR 1·50) were significantly and additively associated with combined prevalent and incident CHD risk. High apoA‐I and low HDL‐cholesterol levels interacted therein in women. Type‐2 diabetes was strongly predicted by HtgW, mediated in men by high apoA‐I/HDL‐C ratio.Conclusion: HtgW is associated with excess inflammatory markers, is predicted in women paradoxically by lower circulating Lp(a) and is associated in both sexes with marked excess cardiometabolic risk to which high apoA‐I/HDL‐C ratio contributes additively. These findings are consistent in women with apoA‐I being oxidized via aggregation to Lp(a).
- 1 January 2013
- Published by ScopeMed in Medical Archives
- Vol. 67 (5) , 308-313
Fostering Diffusion of Scienti and #64257;c Contents of National Society Cardiovascular Journals: the New ESC Search Engine
- 1 January 2013
- Published by ScopeMed in Medical Archives
- Vol. 67 (5) , 308-313
Fostering Diffusion of Scienti and #64257;c Contents of National Society Cardiovascular Journals: the New ESC Search Engine
- 25 October 2012
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (12) , 10907-10914
Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women
The aim of this study was to examine the relationship between APOA4 gene T347S polymorphism with obesity measures and serum lipids in Turkish adults. Randomly selected sample of 1,554 adults (754 men, mean age 50.4 ± 11.9 years and 800 women, mean age 49.6 ± 11.8 years) were included in the study. 346 Women (43.2 %) were postmenopausal. Genotyping was performed by using hybridization probes in real-time PCR. Not men but postmenopausal women, carrying the S347 allele, were associated with 1.5 kg/m2 higher BMI (P = 0.016) and 3.6 cm wider waist circumference (P = 0.005) than postmenopausal T347 homozygotes, controlled for covariates. Logistic regression analyses of this polymorphism, adjusted for age, fasting triglyceride, smoking status, alcohol consumption and physical activity disclosed the rare allele to be associated with obesity in postmenopausal women at an odds of 1.80 (95 % CI 1.09–2.97; P = 0.021). Serum apoB level was lower in S347 allele carriers (110.9 ± 2.9 mg/dL) than in T347 homozygotes (119.0 ± 2.4 mg/dL; P = 0.035) in men but not women. APOA4 T347S polymorphism was unrelated to lipids and other lipoproteins in either gender. The APOA4 S347 allele predisposes to obesity and high waist circumference in Turkish postmenopausal women. ApoB levels are lower only in men in S347 allele carriers.
- 25 October 2012
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (12) , 10907-10914
Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women
The aim of this study was to examine the relationship between APOA4 gene T347S polymorphism with obesity measures and serum lipids in Turkish adults. Randomly selected sample of 1,554 adults (754 men, mean age 50.4 ± 11.9 years and 800 women, mean age 49.6 ± 11.8 years) were included in the study. 346 Women (43.2 %) were postmenopausal. Genotyping was performed by using hybridization probes in real-time PCR. Not men but postmenopausal women, carrying the S347 allele, were associated with 1.5 kg/m2 higher BMI (P = 0.016) and 3.6 cm wider waist circumference (P = 0.005) than postmenopausal T347 homozygotes, controlled for covariates. Logistic regression analyses of this polymorphism, adjusted for age, fasting triglyceride, smoking status, alcohol consumption and physical activity disclosed the rare allele to be associated with obesity in postmenopausal women at an odds of 1.80 (95 % CI 1.09–2.97; P = 0.021). Serum apoB level was lower in S347 allele carriers (110.9 ± 2.9 mg/dL) than in T347 homozygotes (119.0 ± 2.4 mg/dL; P = 0.035) in men but not women. APOA4 T347S polymorphism was unrelated to lipids and other lipoproteins in either gender. The APOA4 S347 allele predisposes to obesity and high waist circumference in Turkish postmenopausal women. ApoB levels are lower only in men in S347 allele carriers.
- 28 June 2012
- Vol. 82 (2) , 170-80
[Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals].
Disclosure of potential conflicts of interest is used by biomedical journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for conflicts of interest disclosure. This paper provides a comprehensive editorial perspective on classical conflict of interest-related issues. New insights into current conflicts of interest policies and practices among European Society of Cardiology national cardiovascular journals, as derived from a cross-sectional survey using a standardized questionnaire, are discussed.
- 28 June 2012
- Vol. 82 (2) , 170-80
[Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals].
Disclosure of potential conflicts of interest is used by biomedical journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for conflicts of interest disclosure. This paper provides a comprehensive editorial perspective on classical conflict of interest-related issues. New insights into current conflicts of interest policies and practices among European Society of Cardiology national cardiovascular journals, as derived from a cross-sectional survey using a standardized questionnaire, are discussed.
- Open Access
- 1 March 2012
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (5) , 587-594
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals
Disclosure of potential conflicts of interest (COIs) is used by biomedical journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into the current COI policies and practices among European Society of Cardiology National Cardiovascular Journals, as derived from a cross-sectional survey using a standardized questionnaire, are discussed.
- 1 March 2012
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (5) , 587-594
Open AccessConflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals
Disclosure of potential conflicts of interest (COIs) is used by biomedical journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into the current COI policies and practices among European Society of Cardiology National Cardiovascular Journals, as derived from a cross-sectional survey using a standardized questionnaire, are discussed.